MLD presenting at AAIC 2022

MLD is happy to announce that our late-breaking abstract “IND-enabling preclinical safety and pharmacokinetic findings of a novel plasmalogen precursor intended for the treatment of Alzheimer’s and other diseases of plasmalogen deficiency” has been accepted into the program for the 2022 Alzheimer’s Association International Conference (AAIC). AAIC is one of the preeminant forums for showcasing the latest developments in the Alzheimer’s space.

The presentation will include the first disclosure of formal FDA-quality safety data for any plasmalogen-based drug or supplement, and represents a pivotal milestone in the company’s progress towards advancing pharmaceutical-grade plasmalogen therapeutics into the clinic.

“Anytime you’re dealing with a purely synthetic compound that is intended to be dosed at relatively high levels, safety is paramount and should be the number one priority,” says Dr. Tara Smith, Executive VP Innovative Therapies at MLD. “These results not only provide that safety window for our lead compound, but also novel insights into the pharmacokinetics of plasmalogen metabolism and distribution.”

Shawn Ritchie, CEO and CSO, and Tara Smith will both be attending AAIC in San Diego between July 31- Aug 4. Exact time of the presentation will be updated when available.